Guardian Pharmacy Services, Inc. (GRDN) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Guardian Pharmacy Services, Inc. is a leading pharmacy services provider for long-term health care facilities (LTCFs), specializing in assisted living and behavioral health facilities. As of March 31, 2026, the company operated 61 pharmacies serving approximately 207,000 residents across 38 states.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $336.6 million | $329.3 million |
| Gross Profit | $76.3 million | $64.3 million |
| Gross Margin | 22.7% | 19.5% |
| Operating Income | $17.7 million | $13.0 million |
| Net Income (GAAP) | $13.5 million | $9.3 million |
| Net Income Attributable to Guardian | $13.3 million | $9.4 million |
| Diluted EPS | $0.21 | $0.15 |
| Adjusted EBITDA | $29.8 million | $23.4 million |
| Cash and Equivalents | $64.9 million | $14.0 million (End of Q1 2025) |
| Operating Cash Flow | $6.1 million | $17.6 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 2.2% year-over-year. However, organic revenue decreased by $11.2 million due to pricing reductions mandated by the Inflation Reduction Act (IRA). This was offset by an $18.5 million revenue increase from acquisitions completed in 2025.
- Volume Expansion: Despite pricing pressure, the number of residents served grew from 189,000 to 207,000, and prescriptions dispensed increased from 6.7 million to 7.4 million.
- Margin Expansion: Gross margin improved to 22.7% from 19.5%, driven by product cost decreases associated with the IRA, which outpaced revenue reductions.
- Expense Increase: Selling, general, and administrative (SG&A) expenses rose 14.2% to $58.6 million, primarily due to increased headcount from organic growth and acquisitions.
- Cash Flow Decline: Operating cash flow decreased significantly to $6.1 million from $17.6 million, attributed to timing differences in working capital (increased accounts receivable and decreased accounts payable) related to IRA implementation.
Guidance, Outlook, and Risks
- Capital Markets Activity: In March 2026, the company completed a follow-on offering of 1.02 million shares at $31.00 per share. Proceeds were used entirely to repurchase and cancel an equal number of Class A shares issued upon the conversion of Class B stock. The company retained no net proceeds from this transaction.
- Share Structure: Approximately 13.5 million shares of Class B common stock automatically converted to Class A common stock during the quarter.
- Legal Settlement: On April 21, 2026 (post-period), the company settled a payor-reimbursement matter, receiving an $8.5 million cash payment. This amount is not reflected in Q1 2026 results.
- Risks: Key risks include the ongoing impact of the Inflation Reduction Act on pricing, regulatory changes, supply chain disruptions, and the ability to maintain relationships with LTCFs and payors.
Investor Verification Checklist
- IRA Impact Sustainability: Verify if the gross margin expansion driven by IRA cost reductions is sustainable or if further price cuts are anticipated.
- Working Capital Trends: Monitor accounts receivable days sales outstanding (DSO) to ensure the Q1 cash flow decline was a temporary timing issue related to IRA billing cycles.
- Organic Growth Metrics: Confirm the trajectory of resident count growth (currently +18,000 residents YoY) to ensure it can offset revenue per resident declines.
- Legal Settlement Timing: Note that the $8.5 million settlement payment received in April 2026 will impact Q2 2026 cash flow and potentially earnings.
- Acquisition Integration: Assess the performance of 2025 acquisitions, which contributed significantly to revenue but also increased SG&A expenses.